Medical Devices

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), a gene-editing technology, has set a record by reaching clinics from the research laboratory in a very short time, as NIH’s Recombinant DNA Advisory Committee has approved the first clinical trial of the technology in the U.S. for coming June. The trial investigators have proposed to exploit this technology to help boost cancer therapies relying on enlisting a patient’s T cells for curing the disease. The indications that are to be investigated include melanoma, multiple myeloma, and sarcoma, and patients whose cancers have stopped responding to therapies will be enrolled. Investigators will first remo...